Longeveron (LGVN) Share-based Compensation (2020 - 2026)
Longeveron's (LGVN) quarterly Share-based Compensation came in at $379000.0 in Q1 2026, up 11.47% year-on-year from $340000.0 in Q1 2025, and up 0.8% quarter-over-quarter from $376000.0 in Q4 2025.
Longeveron (LGVN) Share-based Compensation (2020 - 2026) Analysis & Trends
Longeveron's Share-based Compensation history runs 7 years deep, the most recent figure standing at $379000.0 for Q1 2026.
- On a quarterly basis, Share-based Compensation rose 11.47% year-over-year to $379000.0 in Q1 2026; TTM through Mar 2026 was $1.7 million, a 27.69% decrease from a year earlier, with the FY2025 full-year figure at $1.7 million, down 27.96% from the prior year.
- Share-based Compensation improved to $379000.0 in Q1 2026 per LGVN's latest filing, from $376000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $1.4 million in Q3 2024 and bottomed at $230000.0 in Q2 2024.
- The 5-year median for Share-based Compensation is $448000.0 (2025), against an average of $526647.1.
- Biggest YoY gain for Share-based Compensation was 312.61% in 2022; the steepest drop was 89.49% in 2022.
- Year by year, Share-based Compensation stood at $646000.0 in 2022, then tumbled by 36.07% to $413000.0 in 2023, then fell by 5.57% to $390000.0 in 2024, then fell by 3.59% to $376000.0 in 2025, then increased by 0.8% to $379000.0 in 2026.
- Per Business Quant, the three latest LGVN Share-based Compensation figures stand at $379000.0 (Q1 2026), $376000.0 (Q4 2025), and $448000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 | 379,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 379,000.00 |
| Mar 31, 2026 | 379,000.00 |
| Dec 31, 2025 | 376,000.00 |
| Dec 31, 2025 | 376,000.00 |
| Sep 30, 2025 | 448,000.00 |
| Sep 30, 2025 | 448,000.00 |
| Jun 30, 2025 | 513,000.00 |
| Jun 30, 2025 | 513,000.00 |
| Mar 31, 2025 | 340,000.00 |
| Mar 31, 2025 | 340,000.00 |
| Dec 31, 2024 | 390,000.00 |
| Dec 31, 2024 | 390,000.00 |
| Sep 30, 2024 | 1.41 Mn |
| Sep 30, 2024 | 1.41 Mn |
| Jun 30, 2024 | 230,000.00 |
| Jun 30, 2024 | 230,000.00 |
| Mar 31, 2024 | 295,000.00 |
| Mar 31, 2024 | 295,000.00 |
| Dec 31, 2023 | 413,000.00 |
| Dec 31, 2023 | 413,000.00 |